SureNano Science Ltd. (CSE: SURE | OTCQB: SURNF) with GlucaPharm positions investors at the intersection of breakthrough peptide science, delivery innovation, and high-growth metabolic disease markets.
Core reasons the platform is designed for high-upside value creation.
GEP-44 is a proprietary, monomeric multi-agonist peptide discovered at Syracuse University with patent protection extending to 2042.
Preclinical studies indicate weight-loss and glucose-control outcomes with a favorable tolerability profile relative to current GLP-1 approaches.
The GLP and obesity therapeutic categories are experiencing strong global growth, supporting long-term demand for differentiated options.
Combination of GlucaPharm’s therapeutic asset and SureNano’s public-market platform and delivery expertise supports scalable development.
| Ticker | CSE: SURE | OTCQB: SURNF |
| Headquarters | Vancouver, BC |
| Shares Outstanding | 42,008,799 |
| Options | 1,500,000 |
| Warrants | 15,600,000 |
| Fully Diluted | 59,108,799 |
| Market Cap | ~$9.8M |
| Officer & Director Ownership | ~26% |
| 52 Week High / Low | 0.42 / 0.07 |
A vertically integrated model combining therapeutic innovation and delivery capabilities.
Public Parent
SureNano Science Ltd.
Public-market infrastructure and platform technologies.
Therapeutic Engine
GlucaPharm Inc.
Lead candidate GEP-44 and metabolic therapeutics pipeline.
Value Creation Path
Development to Commercialization
IND progression, clinical execution, and global market optionality.
Milestone-based execution roadmap from late preclinical development toward clinical validation.
2025
Preclinical studies support efficacy and tolerability profile versus current standards.
Q1 2026
GLP-certified toxicology and pharmacology work with CRO collaboration.
Q2 2026
Clinical trial material preparation and CMC process advancement.
Q3 2026
Planned Phase I-III pathway to evaluate human safety and efficacy.
Q4 2026
Regulatory submission and approval progression toward commercialization.
Track SureNano’s public listing and key market references.
Market data widgets are provided by third-party services and may be delayed.
This page contains summary investor information for general reference only. Statements regarding future events may be forward-looking and subject to risks and uncertainties. Investors should review official filings and consult professional advisors before making investment decisions.